Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $23.63 USD
Change Today +0.69 / 3.01%
Volume 59.9K
OMED On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

oncomed pharmaceuticals inc (OMED) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - $29.83
52 Week Low
09/28/15 - $13.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

oncomed pharmaceuticals inc (OMED) Related Bloomberg News

View More Bloomberg News

oncomed pharmaceuticals inc (OMED) Related Businessweek News

No Related Businessweek News Found

oncomed pharmaceuticals inc (OMED) Details

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has completed preclinical trial that targets and inhibits DLL4 and vascular endothelial growth factor (VEGF); Tarextumab (Anti-Notch2/3, OMP-59R5), a human monoclonal antibody that targets the Notch2 and Notch3 receptors that is in Phase II clinical trials; Brontictuzumab (Anti-Notch1, OMP-52M51), a human monoclonal antibody, which completed single-agent Phase I trial for the treatment of solid tumor; and Vantictumab ((Anti-Fzd7, OMP-18R5) that completed a Phase I single-agent trial in tumor patients. Its products also include Ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; Wnt biologic #3, an additional bispecific biologic product candidate in preclinical studies; Wnt small molecule inhibitors, which is in preclinical testing; and RSPO-LGR, a CSC pathway that is in preclinical study of antibodies. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop anti-CSC antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

108 Employees
Last Reported Date: 03/12/15
Founded in 2004

oncomed pharmaceuticals inc (OMED) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $469.5K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $364.7K
Compensation as of Fiscal Year 2014.

oncomed pharmaceuticals inc (OMED) Key Developments

OncoMed Pharmaceuticals, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-19-2015 02:00 PM

OncoMed Pharmaceuticals, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-19-2015 02:00 PM. Venue: The May Fair Hotel, Stratton Street, London, United Kingdom. Speakers: Paul J. Hastings, Chairman, Chief Executive Officer and President.

OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting

OncoMed Pharmaceuticals Inc. presented new preclinical data for anti-DLL4 combined with anti-VEGF and anti-PD1 during the Society for Immunotherapy of Cancer (SITC) Conference. A series of preclinical experiments compared the impact of anti-DLL4/VEGF bispecific and a triple blockade of DLL4-VEGF-PD1 on anti-tumor immune responses. The combination of anti-DLL4/VEGF and anti-PD1 was found to have more potent anti-tumor and enhanced immuno-oncology activity than either agent alone across a number of measures. The triple blockade of DLL4-VEGF-PD1 significantly inhibited tumor growth with more pronounced tumor regression. The addition of anti-DLL4/VEGF also improved anti-tumor activity of anti-PD1 alone in both PD1 responsive and non-responsive cancers in murine models. DLL4 is a ligand within the Notch pathway and plays important roles in regulating cancer stem cells, tumor angiogenesis and pro-tumor immune responses. OncoMed has two clinical agents targeting DLL4: demcizumab (anti-DLL4, OMP-21M18), currently in Phase 2 trials for the treatment of pancreatic cancer and non-small cell lung cancer (NSCLC), and anti-DLL4/VEGF bispecific, (OMP-305B83) currently in a Phase 1a trial in advanced solid tumors. The combination of anti-DLL4/VEGF bispecific with anti-PD1 demonstrated a distinct mechanistic profile versus prior observations of the synergistic combination of anti-DLL4 and anti-PD1 presented at the American Association for Cancer Research 2015 Annual Meeting, suggesting potential for increased T-cell activation, maintenance and memory T-cell function.

OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

OncoMed Pharmaceuticals, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. Revenues for the third quarter 2015 totaled $4.7 million, as compared to $19.0 million in the third quarter of 2014. Revenues were higher in the third quarter of 2014 primarily due to milestone revenues from the GlaxoSmithKline and Bayer collaborations achieved during that period. Net loss for the third quarter 2015 was $24.5 million or $0.81 per basic and diluted share, compared to $5.5 million or $0.18 per basic and diluted share for the same three-month period of 2014. The change in net loss for the third quarter of 2015 was primarily due to an increase in operational expenses and lower milestone revenues. Loss from operations was $24,561,000 against $5,500,000 for the same period a year ago. Loss before provision for income taxes was $24,467,000 against $5,451,000 for the same period a year ago. For the nine months, the company reported collaboration revenue of $19,060,000 against $31,044,000 for the same period a year ago. Loss from operations was $60,737,000 against $34,999,000 for the same period a year ago. Loss before provision for income taxes was $60,594,000 against $34,917,000 for the same period a year ago. Net loss was $60,629,000 compared to $34,954,000 a year ago. Basic and diluted net loss per common share was $2.02 compared to $1.18 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $23.63 USD +0.69

OMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMED.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.8x
Price/Book 28.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ONCOMED PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at